Sentynl
FDA Rejects CUTX-101 for Rare Copper Deficiency Due to Manufacturing Issues
FDA rejection; Menkes disease; CUTX-101; copper deficiency; manufacturing deficiencies; Cyprium Therapeutics; Sentynl Therapeutics; Fortress Biotech
Actionable Insights Powered by AI
FDA rejection; Menkes disease; CUTX-101; copper deficiency; manufacturing deficiencies; Cyprium Therapeutics; Sentynl Therapeutics; Fortress Biotech